<p>2025 年 8 月 8 日- 上午 8:05</p>
<p>加利福尼亚州南旧金山，2025 年 8 月 8 日（GLOBE NEWSWIRE）-- Assembly Biosciences, Inc.（“Assembly Bio”）（纳斯达克：ASMB），一家开发针对严重病毒疾病的创新治疗方案的生物技术公司，今天宣布了一项承销的注册发行（“发行”），总计 5,591,840 股普通股和预先融资的认股权证，购买最多 1,040,820 股普通股，以及附带的 A 类和 B 类认股权证，购买最多 6,632,660 股普通股，普通股及附带的 A 类和 B 类认股权证的综合价格为每股 19.60 美元，预先融资的认股权证及附带的 A 类和 B 类认股权证的综合价格为 19.599 美元。每个预先融资的认股权证的名义行使价格为每股普通股 0.001 美元，并且可以立即行使。每个附带的 A 类认股权证的行使价格为每股普通股 21.60 美元，可以立即行使，并将在以下两者中较早者到期：（i）自发行之日起五年（2030 年 8 月 11 日）和（ii）Assembly Bio 公开宣布其已完成至少 200 名患者的第二阶段临床研究（评估 ABI-5366 与伐昔洛韦）的入组后的 30 天内。每个附带的 B 类认股权证的行使价格为每股普通股 21.60 美元，将在 2026 年 11 月 15 日或之后可行使，并将在 2026 年 12 月 31 日到期，前提是如果 Assembly Bio 在 2026 年 11 月 15 日之前公开宣布其已获得至少 7500 万美元的非稀释性资本以进行合作协议，则每个 B 类认股权证将自动完全终止并失效，不再可行使。</p>
<p>此次发行包括来自新投资者和现有投资者的参与，包括 Commodore Capital、黑石多资产投资、Farallon Capital Management, L.L.C.、Janus Henderson Investors、RA Capital Management（一家大型投资管理公司）以及其他专注于医疗保健的基金。</p>
<p>除了此次发行，Assembly Bio 还宣布 Gilead Sciences, Inc.（“Gilead”）将在一项私募配售（“私募配售”）中购买 2,295,920 股普通股及附带的 A 类和 B 类认股权证，购买最多 2,295,920 股普通股，价格与上述发行价格相同。私募配售中的证券销售将不在 1933 年证券法（修订版）（“证券法”）下注册。</p>
<p>此次发行和私募配售预计将于 2025 年 8 月 11 日完成，前提是满足惯例的交割条件。发行的完成和私募配售的完成相互依赖。</p>
<p>Assembly Bio 计划将此次发行和私募配售的净收益用于一般企业用途。</p>
<p>Guggenheim Securities 担任此次发行的主承销商。瑞穗证券也担任此次发行的承销商。</p>
<p>与此次发行相关的证券注册声明已向证券交易委员会（“SEC”）提交并已生效。与此次发行相关的初步招股说明书补充和最终招股说明书补充将提交给 SEC，并将在 SEC 的网站 www.sec.gov 上提供。当可用时，初步招股说明书补充和最终招股说明书补充的副本可以通过联系 Guggenheim Securities, LLC，注意：股权承销部，330 Madison Avenue, New York, New York 10017，电话（212）518-9544，或通过电子邮件 GSEquityProspectusDelivery@guggenheimpartners.com 获取；或联系瑞穗证券，c/o Mizuho Securities USA LLC, 1271 Avenue of the Americas, New York, New York 10020，或通过电子邮件 US-ECM@mizuhogroup.com，注意：股权资本市场。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的邀请，也不构成在任何州或司法管辖区内进行此类要约、邀请或销售的要约，除非在任何此类州或司法管辖区的证券法下注册或资格之前。</p>
<p><strong>关于 Assembly Biosciences</strong></p>
<p>Assembly Biosciences 是一家生物技术公司，致力于开发创新的小分子治疗药物，旨在改变严重病毒疾病的治疗路径，并改善全球患者的生活。Assembly Bio 由一支在病毒药物开发领域经验丰富的领导团队领导，致力于改善因疱疹病毒、乙型肝炎病毒（HBV）和丙型肝炎病毒（HDV）感染而面临严重慢性影响的患者的治疗结果。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的信息包含前瞻性陈述，这些陈述受到某些风险和不确定性的影响，可能导致实际结果与预期有重大差异。这些前瞻性陈述包括关于拟议发行和拟议私募的声明，包括预期的时间和完成情况以及由此产生的收益的使用。这些风险和不确定性包括：Assembly Bio 维持财务资源和确保继续其研究活动、临床研究、其他业务运营所需的额外资金的能力；Assembly Bio 实现与 Gilead 合作的潜在利益的能力，包括合作和股权投资的所有财务方面；Assembly Bio 启动和完成涉及其治疗产品候选者的临床研究的能力，包括 Assembly Bio 与 Gilead 合作所考虑的研究，是否能够在当前预期的时间框架内或根本上完成；来自临床或非临床研究的安全性和有效性数据可能不支持 Assembly Bio 产品候选者的进一步开发；临床和非临床数据可能无法将 Assembly Bio 的产品候选者与其他公司的候选者区分开；政府监管变化的潜在影响，包括由于 2025 年美国政府更换而导致的变化；非临床研究的结果可能无法代表临床环境中的疾病行为，并且可能无法预测临床研究的结果；以及 Assembly Bio 在向 SEC 提交的报告中不时识别的其他风险。您被敦促考虑包含 “可能”、“将”、“会”、“能够”、“应该”、“可能”、“相信”、“希望”、“估计”、“项目”、“潜在”、“期待”、“计划”、“预期”、“打算”、“继续”、“预测”、“设计”、“目标” 或这些词的否定形式或其他可比词的声明为不确定和前瞻性。Assembly Bio 打算将这些前瞻性陈述纳入《证券法》第 27A 条和《1934 年证券交易法》第 21E 条修订版中包含的安全港条款。有关 Assembly Bio 风险和不确定性的更多信息详见 Assembly Bio 向 SEC 提交的文件中的 “风险因素” 部分，包括其最近的 10-K 表格年度报告、10-Q 表格季度报告和 8-K 表格当前报告。除法律要求外，Assembly Bio 不承担公开更新任何前瞻性陈述的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>联系方式</strong></p>
<p><strong>投资者与企业事务：</strong></p>
<p>Shannon Ryan</p>
<p>高级副总裁，投资者关系、企业事务及联盟管理</p>
<p>(415) 738-2992</p>
<p>investor_relations@assemblybio.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09EazRNU00zTURnNU5qUXpJekl3TWpZek9UTT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09EazRNU00zTURnNU5qUXpJekl3TWpZek9UTT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNjOTlmMjEtNDM5MC00OGI1LWI0NjUtODU2NWExYzYyYjIxLTEwMzk3NzAtMjAyNS0wOC0wOC1lbg==/tiny/Assembly-Biosciences-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNjOTlmMjEtNDM5MC00OGI1LWI0NjUtODU2NWExYzYyYjIxLTEwMzk3NzAtMjAyNS0wOC0wOC1lbg==/tiny/Assembly-Biosciences-Inc-.png"/></p>

Assembly生物科技

<p>Assembly Biosciences, Inc. 宣布了一项 1.75 亿美元的股权融资定价，其中包括 5,591,840 股普通股和预先融资的认股权证的承销发行。发行价格定为每股 19.60 美元，参与投资者包括吉利德科学（Gilead Sciences），该公司将在私募中购买 2,295,920 股。融资所得将用于一般企业用途，交易预计将在 2025 年 8 月 11 日完成，具体需满足惯例条件</p>

<p>08/08/2025 - 08:05 AM</p>
<div class="lb-trans"><p>2025 年 8 月 8 日- 上午 8:05</p>
</div><p>SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599. Each pre-funded warrant will have a nominal exercise price of $0.001 per share of common stock and will be immediately exercisable. Each accompanying Class A warrant will have an exercise price of $21.60 per share of common stock, will be immediately exercisable and will expire on the earlier of (i) five years from the date of issuance (August 11, 2030) and (ii) the date that is 30 days after the public announcement that Assembly Bio has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. Each accompanying Class B warrant will have an exercise price of $21.60 per share of common stock, will be exercisable on or after November 15, 2026 and will expire on December 31, 2026, provided that each Class B warrant will automatically terminate in full and be extinguished and shall no longer be exercisable in the event that Assembly Bio publicly announces prior to November 15, 2026 that it has received at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreement.</p>
<div class="lb-trans"><p>加利福尼亚州南旧金山，2025 年 8 月 8 日（GLOBE NEWSWIRE）-- Assembly Biosciences, Inc.（“Assembly Bio”）（纳斯达克：ASMB），一家开发针对严重病毒疾病的创新治疗方案的生物技术公司，今天宣布了一项承销的注册发行（“发行”），总计 5,591,840 股普通股和预先融资的认股权证，购买最多 1,040,820 股普通股，以及附带的 A 类和 B 类认股权证，购买最多 6,632,660 股普通股，普通股及附带的 A 类和 B 类认股权证的综合价格为每股 19.60 美元，预先融资的认股权证及附带的 A 类和 B 类认股权证的综合价格为 19.599 美元。每个预先融资的认股权证的名义行使价格为每股普通股 0.001 美元，并且可以立即行使。每个附带的 A 类认股权证的行使价格为每股普通股 21.60 美元，可以立即行使，并将在以下两者中较早者到期：（i）自发行之日起五年（2030 年 8 月 11 日）和（ii）Assembly Bio 公开宣布其已完成至少 200 名患者的第二阶段临床研究（评估 ABI-5366 与伐昔洛韦）的入组后的 30 天内。每个附带的 B 类认股权证的行使价格为每股普通股 21.60 美元，将在 2026 年 11 月 15 日或之后可行使，并将在 2026 年 12 月 31 日到期，前提是如果 Assembly Bio 在 2026 年 11 月 15 日之前公开宣布其已获得至少 7500 万美元的非稀释性资本以进行合作协议，则每个 B 类认股权证将自动完全终止并失效，不再可行使。</p>
</div><p>The offering includes participation from new and existing investors, including Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, L.L.C., Janus Henderson Investors, RA Capital Management, a large investment management firm, and other healthcare dedicated funds.</p>
<div class="lb-trans"><p>此次发行包括来自新投资者和现有投资者的参与，包括 Commodore Capital、黑石多资产投资、Farallon Capital Management, L.L.C.、Janus Henderson Investors、RA Capital Management（一家大型投资管理公司）以及其他专注于医疗保健的基金。</p>
</div><p>In addition to the offering, Assembly Bio announced that Gilead Sciences, Inc. (“Gilead”) will purchase 2,295,920 shares of common stock and accompanying Class A warrants and Class B warrants to purchase up to an aggregate of 2,295,920 shares of common stock in a private placement (the “private placement”) at a price per share, together with accompanying warrants, equal to the offering price described above. The sale of the securities in the private placement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”).</p>
<div class="lb-trans"><p>除了此次发行，Assembly Bio 还宣布 Gilead Sciences, Inc.（“Gilead”）将在一项私募配售（“私募配售”）中购买 2,295,920 股普通股及附带的 A 类和 B 类认股权证，购买最多 2,295,920 股普通股，价格与上述发行价格相同。私募配售中的证券销售将不在 1933 年证券法（修订版）（“证券法”）下注册。</p>
</div><p>The offering and the private placement are expected to close on August 11, 2025, subject to the satisfaction of customary closing conditions. The closing of the offering and the closing of the private placement are contingent upon one another.</p>
<div class="lb-trans"><p>此次发行和私募配售预计将于 2025 年 8 月 11 日完成，前提是满足惯例的交割条件。发行的完成和私募配售的完成相互依赖。</p>
</div><p>Assembly Bio plans to use the net proceeds from the offering and the private placement for general corporate purposes.</p>
<div class="lb-trans"><p>Assembly Bio 计划将此次发行和私募配售的净收益用于一般企业用途。</p>
</div><p>Guggenheim Securities is acting as lead book-running manager for the offering. Mizuho is also acting as a book-running manager for the offering.</p>
<div class="lb-trans"><p>Guggenheim Securities 担任此次发行的主承销商。瑞穗证券也担任此次发行的承销商。</p>
</div><p>Registration statements relating to the securities being sold in the offering have been filed with the Securities and Exchange Commission (“SEC”) and are effective. A preliminary prospectus supplement and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and final prospectus supplement may be obtained by contacting Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Mizuho, c/o Mizuho Securities USA LLC, 1271 Avenue of the Americas, New York, New York 10020 or by email at US-ECM@mizuhogroup.com, Attention: Equity Capital Markets.</p>
<div class="lb-trans"><p>与此次发行相关的证券注册声明已向证券交易委员会（“SEC”）提交并已生效。与此次发行相关的初步招股说明书补充和最终招股说明书补充将提交给 SEC，并将在 SEC 的网站 www.sec.gov 上提供。当可用时，初步招股说明书补充和最终招股说明书补充的副本可以通过联系 Guggenheim Securities, LLC，注意：股权承销部，330 Madison Avenue, New York, New York 10017，电话（212）518-9544，或通过电子邮件 GSEquityProspectusDelivery@guggenheimpartners.com 获取；或联系瑞穗证券，c/o Mizuho Securities USA LLC, 1271 Avenue of the Americas, New York, New York 10020，或通过电子邮件 US-ECM@mizuhogroup.com，注意：股权资本市场。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的邀请，也不构成在任何州或司法管辖区内进行此类要约、邀请或销售的要约，除非在任何此类州或司法管辖区的证券法下注册或资格之前。</p>
</div><p><strong>About Assembly Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Assembly Biosciences</strong></p>
</div><p>Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections.</p>
<div class="lb-trans"><p>Assembly Biosciences 是一家生物技术公司，致力于开发创新的小分子治疗药物，旨在改变严重病毒疾病的治疗路径，并改善全球患者的生活。Assembly Bio 由一支在病毒药物开发领域经验丰富的领导团队领导，致力于改善因疱疹病毒、乙型肝炎病毒（HBV）和丙型肝炎病毒（HDV）感染而面临严重慢性影响的患者的治疗结果。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These forward-looking statements include statements about the proposed offering and the proposed private placement, including the expected timing and completion thereof and the use of proceeds therefrom. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, other business operations and continue as a going concern; Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data may not differentiate Assembly Bio’s product candidates from other companies’ candidates; potential effects of changes in government regulation, including as a result of the change in U.S. administration in 2025; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the SEC. You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿中的信息包含前瞻性陈述，这些陈述受到某些风险和不确定性的影响，可能导致实际结果与预期有重大差异。这些前瞻性陈述包括关于拟议发行和拟议私募的声明，包括预期的时间和完成情况以及由此产生的收益的使用。这些风险和不确定性包括：Assembly Bio 维持财务资源和确保继续其研究活动、临床研究、其他业务运营所需的额外资金的能力；Assembly Bio 实现与 Gilead 合作的潜在利益的能力，包括合作和股权投资的所有财务方面；Assembly Bio 启动和完成涉及其治疗产品候选者的临床研究的能力，包括 Assembly Bio 与 Gilead 合作所考虑的研究，是否能够在当前预期的时间框架内或根本上完成；来自临床或非临床研究的安全性和有效性数据可能不支持 Assembly Bio 产品候选者的进一步开发；临床和非临床数据可能无法将 Assembly Bio 的产品候选者与其他公司的候选者区分开；政府监管变化的潜在影响，包括由于 2025 年美国政府更换而导致的变化；非临床研究的结果可能无法代表临床环境中的疾病行为，并且可能无法预测临床研究的结果；以及 Assembly Bio 在向 SEC 提交的报告中不时识别的其他风险。您被敦促考虑包含 “可能”、“将”、“会”、“能够”、“应该”、“可能”、“相信”、“希望”、“估计”、“项目”、“潜在”、“期待”、“计划”、“预期”、“打算”、“继续”、“预测”、“设计”、“目标” 或这些词的否定形式或其他可比词的声明为不确定和前瞻性。Assembly Bio 打算将这些前瞻性陈述纳入《证券法》第 27A 条和《1934 年证券交易法》第 21E 条修订版中包含的安全港条款。有关 Assembly Bio 风险和不确定性的更多信息详见 Assembly Bio 向 SEC 提交的文件中的 “风险因素” 部分，包括其最近的 10-K 表格年度报告、10-Q 表格季度报告和 8-K 表格当前报告。除法律要求外，Assembly Bio 不承担公开更新任何前瞻性陈述的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p><strong>Investor and Corporate:</strong></p>
<div class="lb-trans"><p><strong>投资者与企业事务：</strong></p>
</div><p>Shannon Ryan</p>
<div class="lb-trans"><p>Shannon Ryan</p>
</div><p>SVP, Investor Relations, Corporate Affairs and Alliance Management</p>
<div class="lb-trans"><p>高级副总裁，投资者关系、企业事务及联盟管理</p>
</div><p>(415) 738-2992</p>
<div class="lb-trans"><p>(415) 738-2992</p>
</div><p>investor_relations@assemblybio.com</p>
<div class="lb-trans"><p>investor_relations@assemblybio.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09EazRNU00zTURnNU5qUXpJekl3TWpZek9UTT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUwODk4MSM3MDg5NjQzIzIwMjYzOTM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNjOTlmMjEtNDM5MC00OGI1LWI0NjUtODU2NWExYzYyYjIxLTEwMzk3NzAtMjAyNS0wOC0wOC1lbg==/tiny/Assembly-Biosciences-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGNjOTlmMjEtNDM5MC00OGI1LWI0NjUtODU2NWExYzYyYjIxLTEwMzk3NzAtMjAyNS0wOC0wOC1lbg==/tiny/Assembly-Biosciences-Inc-.png"/></p>

Assembly 生物科技宣布 1.75 亿美元股权融资的定价 | ASMB 股票新闻